C12N 2310/3527
Other alkyl chain
C12N2310/3527 (Other alkyl chain) appears on 173 US grants and 93 published applications in this corpus.
Search patents in C12N- Granted patents
- 173
- Published applications
- 93
- Assignees
- 45
- Inventors
- 173
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 4 | 0 |
| 1996 | 14 | 0 |
| 1997 | 22 | 0 |
| 1998 | 16 | 0 |
| 1999 | 19 | 0 |
| 2000 | 13 | 0 |
| 2001 | 12 | 1 |
| 2002 | 18 | 5 |
| 2003 | 7 | 11 |
| 2004 | 3 | 7 |
| 2005 | 4 | 3 |
| 2006 | 5 | 1 |
| 2007 | 1 | 2 |
| 2008 | 0 | 4 |
| 2009 | 0 | 3 |
| 2010 | 0 | 1 |
| 2011 | 2 | 2 |
| 2012 | 1 | 1 |
| 2013 | 2 | 4 |
| 2014 | 2 | 7 |
| 2015 | 3 | 14 |
| 2016 | 7 | 3 |
| 2017 | 2 | 2 |
| 2018 | 2 | 3 |
| 2019 | 3 | 3 |
| 2020 | 0 | 2 |
| 2021 | 3 | 2 |
| 2022 | 0 | 3 |
| 2023 | 1 | 3 |
| 2024 | 2 | 5 |
| 2025 | 1 | 1 |
| 2026 | 2 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Complement component C5 iRNA compositions and methods of use thereof31 Mar 2026US 12,590,305 B2Alnylam Pharmaceuticals, Inc.
- Single-stranded RNA-editing oligonucleotides10 Feb 2026US 12,545,911 B2ProQR Therapeutics II B.V.
- Nucleoside derivative and use thereof26 Aug 2025US 12,398,170 B2National University Corporation Tokai National Higher Education and Research System
- Single-stranded RNA-editing oligonucleotides25 Jun 2024US 12,018,257 B2ProQR Therapeutics II B.V.
- Complement component C5 iRNA compositions and methods of use thereof16 Jan 2024US 11,873,491 B2Alnylam Pharmaceuticals, Inc.
- Sirna targeting angiotensinogen and pharmaceutical use of sirna19 Jun 2025US 2025/0197853 A1Tuojie Biotech (Shanghai) Co., Ltd.
- Single-stranded rna-editing oligonucleotides19 Dec 2024US 2024/0417721 A1ProQR Therapeutics II B.V.
- Stabilization of oligonucleotide and oligonucleotide-protein complex using alkylated phosphate19 Sep 2024US 2024/0309372 A1University of Massachusetts
- Ligand-binding nucleic acid complex22 Aug 2024US 2024/0279655 A1Rena Therapeutics Inc.
- Complement component c5 irna compositions and methods of use thereof15 Aug 2024US 2024/0271136 A1Alnylam Pharmaceuticals, Inc.
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved663US 5,403,711 AUniversity of Iowa Research Foundation · 1995
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996